About KAICO
KAICO is a company based in Fukuoka (Japan) founded in 2018. KAICO has raised $8.15 million across 5 funding rounds from investors including Sojitz, Tokyo Century and FFG Venture Business Partners. KAICO offers products and services including Protein Expression Service, Custom Protein Expression, Trial Services, Research Reagents, and Supplements. KAICO operates in a competitive market with competitors including Qkine, Core Biogenesis, Future Fields, Protera and Algenex, among others.
- Headquarter Fukuoka, Japan
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Kaico Ltd.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$8.15 M (USD)
in 5 rounds
-
Latest Funding Round
$3.77 M (USD), Series B
Apr 15, 2025
-
Investors
Sojitz
& 9 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of KAICO
KAICO offers a comprehensive portfolio of products and services, including Protein Expression Service, Custom Protein Expression, Trial Services, Research Reagents, and Supplements.
Offers custom protein production using silkworm system for research.
Provides tailored protein expression services for client needs.
Delivers trial protein expression to test feasibility.
Supplies reagents derived from silkworm-expressed proteins.
Develops supplements using recombinant proteins for various uses.
Creates veterinary and human vaccines via protein expression.
Funding Insights of KAICO
KAICO has successfully raised a total of $8.15M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $3.77 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in KAICO
KAICO has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Sojitz, Tokyo Century and FFG Venture Business Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Venture capital firm investing in early-stage startups
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for KAICO
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by KAICO
Investment portfolio details for KAICO
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - KAICO
Detailed financials for KAICO
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kaico Comparisons
Peer comparison for KAICO
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of KAICO
KAICO operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Qkine, Core Biogenesis, Future Fields, Protera and Algenex, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Animal-free growth factors are developed for life science applications.
|
|
| Locked | Locked | Locked |
UBaaS platform for plant-based recombinant protein bioproduction is offered.
|
|
| Locked | Locked | Locked |
Serum-free bioactive growth factors and recombinant proteins are biomanufactured.
|
|
| Locked | Locked | Locked |
Protein-based enzyme technologies are developed using deep learning algorithms.
|
|
| Locked | Locked | Locked |
Developer of recombinant biologics for animal and human health
|
Detailed competitors of KAICO
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kaico
Complete news archive for KAICO
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about KAICO
KAICO was founded in 2018.
KAICO is headquartered in Fukuoka, Japan. It is registered at Fukuoka, Fukuoka, Japan.
Kenta Yamato is the current CEO of KAICO.
KAICO is a funded company, having raised a total of $8.15M across 5 funding rounds to date.
KAICO was founded in 2018 and is based in Fukuoka, Japan, within the biotechnology sector. A portfolio of proteins, cytokines, and enzymes is produced using a silkworm-baculovirus expression system as the primary technology. These products serve applications in medicine and diagnostic reagents. Contract research services for protein expression are also provided, alongside specific items such as PNGase-F, bFGF, and NucA.
KAICO's top competitors include Future Fields, Qkine and Core Biogenesis.
KAICO offers Protein Expression Service, Custom Protein Expression, Trial Services, Research Reagents, and 2 more products and services.
KAICO has 10 investors. Key investors include Sojitz, Tokyo Century, FFG Venture Business Partners, ITOCHU Technology Ventures, and Mizuho Capital.